Qualigen Therapeutics Dividend

Dividend criteria checks 0/6

Qualigen Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$1.98
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M

Aug 16

Qualigen Therapeutics files mixed shelf offering of up to $150M

Jul 29

Qualigen partners Hande Sciences to support its application enabling studies for QN-302

Jul 06

Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?

Mar 08

We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate

Nov 23

Is Qualigen Therapeutics (NASDAQ:QLGN) In A Good Position To Deliver On Growth Plans?

Apr 05

Qualigen nabs additional U.S. patent for ALAN anticancer platform

Dec 15

Qualigen Therapeutics EPS misses by $0.61, misses on revenue

Nov 13

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if QLGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QLGN's dividend payments have been increasing.

Dividend Yield vs Market

Qualigen Therapeutics Dividend Yield vs Market

How does QLGN dividend yield compare to the market?
Segment	Dividend Yield
Company (QLGN)	n/a
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.8%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (QLGN)	n/a

Notable Dividend: Unable to evaluate QLGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QLGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate QLGN's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as QLGN has not reported any payouts.

Qualigen Therapeutics Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Qualigen Therapeutics, Inc. announced delayed annual 10-K filing

Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital Anstalt

Consensus revenue estimates decrease by 14%, EPS upgraded

Qualigen Therapeutics Receives a Letter from the Nasdaq Stock Market

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Consensus EPS estimates fall by 57%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Qualigen Therapeutics Announces UD FDA IND Clearance to Initiate Phase 1 Clinical Trial of Qn-302 for Treatment of Advanced or Metastatic Solid Tumors

Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. (NasdaqCM:QLGN).

Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. (NasdaqCM:QLGN).

New minor risk - Share price stability

Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and Director

Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics, Inc., Annual General Meeting, Jul 13, 2023

Qualigen Therapeutics, Inc. Announces the Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and A Director, Effective June 16, 2023

Price target decreased by 23% to US$27.00

Consensus revenue estimates decrease by 12%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Qualigen Therapeutics, Inc. Initiates Good Laboratory Practice Toxicology Studies on QN-302

Qualigen Therapeutics, Inc. Announces Executive Changes

Qualigen Therapeutics, Inc. announced that it expects to receive $3.3 million in funding

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Qualigen Therapeutics, Inc. Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Consensus forecasts updated

High number of new and inexperienced directors

Qualigen Therapeutics, Inc., Annual General Meeting, Oct 28, 2022

Nasdaq Grants Qualigen Therapeutics 180-Day Extension to February 27, 2023 to Regain Compliance with the Minimum Bid Price Requirement

High number of new and inexperienced directors

Consensus forecasts updated

Consensus revenue estimates increase by 10%

Qualigen Therapeutics, Inc. Announces Formation and First Meeting of QN-302 Scientific Advisory Board

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M

Qualigen Therapeutics, Inc. Reports Positive Qn-247 Readout in Triple Negative Breast Cancer in Vivo Model

Qualigen Therapeutics files mixed shelf offering of up to $150M

Qualigen partners Hande Sciences to support its application enabling studies for QN-302

Price target decreased to US$5.75

Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials

Qualigen Therapeutics, Inc. (NasdaqCM:QLGN) completed the acquisition of a 53% stake in NanoSynex Ltd. from shareholder.

Qualigen Therapeutics, Inc. (NasdaqCM:QLGN) entered into definitive agreement to acquire an unknown majority stake in NanoSynex Ltd. from shareholder.

Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?

We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate

Price target decreased to US$8.25

Second quarter 2021 earnings released: US$0.18 loss per share (vs US$2.12 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.13 loss per share (vs US$0.16 loss in 1Q 2020)

Is Qualigen Therapeutics (NASDAQ:QLGN) In A Good Position To Deliver On Growth Plans?

Qualigen Therapeutics, Inc. Announces Management Changes

New 90-day low: US$2.90

New 90-day high: US$4.23

New 90-day low: US$3.20

Qualigen Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Qualigen Therapeutics, Inc. Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology

Qualigen nabs additional U.S. patent for ALAN anticancer platform

Qualigen Therapeutics, Inc. Appoints Sidney Emery, Jr. as A Member of the Board

Qualigen Therapeutics, Inc. Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials

New 90-day low: US$3.34

Qualigen Therapeutics EPS misses by $0.61, misses on revenue

New 90-day low: US$3.97

Qualigen Therapeutics Enters into Commercialization Agreement for its FastPack® Diagnostic Products in China

Qualigen Therapeutics Expands Research Agreement with University of Louisville for ALAN Cancer Drug Candidate

Qualigen Therapeutics, Inc. and University of Louisville Announce Filing of U.S. Provisional Patent Application for the Use of AS1411 to Prevent Viral Infections

First quarter earnings released

Qualigen Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $9.999996 million.

Qualigen Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8 million.

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies